MetaADEDB 2.0 @ LMMD
Prazosin
(WFXFYZULCQKPIP-UHFFFAOYSA-N)
Structure
SMILES
COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1.Cl
Molecular Formula:
C19H22ClN5O4
Molecular Weight:
419.862
Log P:
3.1707
Hydrogen Bond Acceptor:
9
Hydrogen Bond Donor:
2
TPSA:
106.95
CAS Number(s):
19237-84-4
Synonym(s)
1.
Prazosin
2.
Furazosin
3.
Minipress
4.
Pratsiol
5.
Prazosin HCL
6.
Prazosin Hydrochloride
7.
HCL, Prazosin
8.
Hydrochloride, Prazosin
External Link(s)
MeSHD011224
PubChem Compound657274
68546
BindingDB50299207
ChEBI8365
CHEMBLCHEMBL1558
KEGGdr:D00609
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1SyncopeFAERS: 11
Canada Vigilance: 1		Canada Vigilance
US FAERS
2DizzinessFAERS: 10US FAERS
3HeadacheFAERS: 10US FAERS
4HypotensionFAERS: 8
Canada Vigilance: 2		Canada Vigilance
US FAERS
5Chest PainFAERS: 4US FAERS
6Drug ineffective for unapproved indicationFAERS: 4US FAERS
7SomnolenceFAERS: 4US FAERS
8Depressed Level of ConsciousnessFAERS: 3US FAERS
9Drug ineffectiveFAERS: 3US FAERS
10Memory impairmentFAERS: 3US FAERS
11Product use in unapproved indicationFAERS: 3US FAERS
12BlindnessFAERS: 2US FAERS
13Blood pressure inadequately controlledFAERS: 2US FAERS
14Blood urea increasedFAERS: 2US FAERS
15Cerebrovascular accidentFAERS: 2US FAERS
16Drug DependenceFAERS: 2US FAERS
17FatigueFAERS: 2US FAERS
18FlushingFAERS: 2US FAERS
19MalaiseFAERS: 2US FAERS
20Myocardial InfarctionFAERS: 2US FAERS
21NauseaFAERS: 2US FAERS
22PriapismFAERS: 2US FAERS
23UrticariaFAERS: 2US FAERS
24VomitingFAERS: 2US FAERS
25AmnesiaFAERS: 1US FAERS
26AngioedemaFAERS: 1US FAERS
27ArthralgiaFAERS: 1US FAERS
28AstheniaFAERS: 1US FAERS
29Blood creatinine increasedFAERS: 1US FAERS
30Blood pressure fluctuationFAERS: 1US FAERS
31Chest discomfortFAERS: 1US FAERS
32Completed SuicideFAERS: 1US FAERS
33Consciousness fluctuatingFAERS: 1US FAERS
34DehydrationFAERS: 1US FAERS
35Diabetes MellitusFAERS: 1US FAERS
36Drug effective for unapproved indicationFAERS: 1US FAERS
37Feeling abnormalFAERS: 1US FAERS
38FractureFAERS: 1US FAERS
39HypersensitivityFAERS: 1US FAERS
40Iatrogenic injuryFAERS: 1US FAERS
41Inappropriate schedule of product administrationFAERS: 1US FAERS
42Incorrect dose administeredFAERS: 1US FAERS
43Intentional product misuseFAERS: 1US FAERS
44Intentional product use issueFAERS: 1US FAERS
45LacerationFAERS: 1US FAERS
46Limb discomfortFAERS: 1US FAERS
47Lip swellingFAERS: 1US FAERS
48Medication ErrorFAERS: 1US FAERS
49Medication residue presentFAERS: 1US FAERS
50Mental impairmentFAERS: 1US FAERS
51PalpitationsFAERS: 1US FAERS
52Peripheral swellingFAERS: 1US FAERS
53Product difficult to swallowFAERS: 1US FAERS
54Product use complaintFAERS: 1US FAERS
55Product use issueFAERS: 1US FAERS
56PruritusFAERS: 1US FAERS
57Reaction to drug excipientsFAERS: 1US FAERS
58Respiratory FailureFAERS: 1US FAERS
59Suicide attemptFAERS: 1US FAERS
60Therapeutic response changedFAERS: 1US FAERS
61TremorFAERS: 1US FAERS
62Troponin increasedFAERS: 1US FAERS
63Urinary RetentionFAERS: 1US FAERS
64VertigoFAERS: 1US FAERS
65Weight decreasedFAERS: 1US FAERS
66Wrong technique in drug usage processFAERS: 1US FAERS
67AlopeciaCanada Vigilance: 1Canada Vigilance
68Anaphylactoid ReactionCanada Vigilance: 1Canada Vigilance
69DiplopiaCanada Vigilance: 1Canada Vigilance
70Erectile dysfunctionCanada Vigilance: 1Canada Vigilance
71GlossitisCanada Vigilance: 1Canada Vigilance
72PolyuriaCanada Vigilance: 1Canada Vigilance
73Rectal tenesmusCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.